The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
Microbiotica Raises $48 Million Series C to Advance Pipeline into Phase 2 Clinical Development• Prokarium: Leading the Evolution of Bacterial Immunotherapy, the Next Frontier in Cancer Treatment• Claude Discovers Novel Enzyme System with CRISPR-like Repeats• New Clinical Study Aims to Find Out if FMT capsules could help better manage anorexia• MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination• Evvy Raises $40M Series B to Scale AI-Powered Precision Diagnostics & Care Platform for Women’s Health•

Category: Regulatory & Policy

MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination
Clinical & Manufacturing

MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination

SEP 18, 2026
Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02
Infectious Disease & AMR

Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02

SEP 15, 2026
A pioneering gut bacterium passes Europe’s food-safety review under the EU Novel Food Regulation
Editor's Choice

A pioneering gut bacterium passes Europe’s food-safety review under the EU Novel Food Regulation

SEP 1, 2026
AOB Pharma receives EMA positive decision on the Pediatric Investigation Plan for development of B244
Pharma & Human Health

AOB Pharma receives EMA positive decision on the Pediatric Investigation Plan for development of B244

DEC 9, 2025
MaaT Pharma Submits Marketing Authorization Application to the European Medicines Agency (EMA) for Xervyteg®
Finance

MaaT Pharma Submits Marketing Authorization Application to the European Medicines Agency (EMA) for Xervyteg®

JUN 3, 2025
Hervé Affagard talks Phase 3 results, the regulatory landscape and industry collaborations
Clinical & Manufacturing

Hervé Affagard talks Phase 3 results, the regulatory landscape and industry collaborations

FEB 20, 2025
Health Canada Licenses Probiotical’s PROBIAL DERM® for Eczema and Atopic Dermatitis Claims
Biotics and Supplements

Health Canada Licenses Probiotical’s PROBIAL DERM® for Eczema and Atopic Dermatitis Claims

OCT 22, 2024
Neu-REFIX Beta glucan receives rare pediatric disease and orphan drug designations from the FDA for treatment of Duchenne Muscular Dystrophy
Pharma & Human Health

Neu-REFIX Beta glucan receives rare pediatric disease and orphan drug designations from the FDA for treatment of Duchenne Muscular Dystrophy

SEP 24, 2024
ProDigest Awarded FDA Contract to Provide a Preclinical Gastrointestinal Model: SHIME®
Gastrointestinal

ProDigest Awarded FDA Contract to Provide a Preclinical Gastrointestinal Model: SHIME®

SEP 16, 2024
FDA cracks down on illegal probiotic product usage for hospitalised preterm infants
Biotics and Supplements

FDA cracks down on illegal probiotic product usage for hospitalised preterm infants

NOV 30, 2023
EMA adopts guidelines on veterinary medicinal products for phage therapy.
Animal Health

EMA adopts guidelines on veterinary medicinal products for phage therapy.

OCT 29, 2023